Navigation Links
Thomson Scientific Introduces a New Quarterly Report Identifying the 'Movers and Shakers' in the U.S. Generics Industry
Date:1/8/2008

Report Draws On Strategic Intelligence and Competitive Analysis Information

From Newport Horizon Global(TM)

PHILADELPHIA and LONDON, Jan. 9 /PRNewswire-FirstCall/ -- Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, has released the first issue of Movers and Shakers. This newest report in the Pharma Matters series analyzes the U.S. generics market from July to September 2007, profiles some of the companies breaking into the market, and highlights molecule patents currently being challenged.

Movers and Shakers reviews the U.S. generics market using strategic intelligence and competitive analysis information drawn from Thomson Scientific's Newport Horizon Global, the critical product targeting and global business development system from the industry authority on the global generics market, in order to assess one of the world's most important pharmaceutical markets.

"Because of the dynamic nature of the generics market in the U.S., the common perception is that the market is relatively easy to break into," said Kate Kuhrt, director, Generics and API Intelligence, Thomson Scientific. "However, our research has shown that there is huge competition between the incumbents and new companies vying for a slice of the market, and clearly there will be winners and losers. Ours is the first quarterly report to identify the real 'movers and shakers' within the generics market."

The first quarterly report covers the period of July to September 2007, and highlights the key indicators of the state of play of the industry. These are:

Abbreviated New Drug Applications (ANDA): An ANDA is the first step in the process a company needs to follow in order to release a generic drug in the U.S. and is submitted to the FDA to prove that the generic version is equivalent to the brand name drug (reference listed drug).

Paragraph IV challenges: A generic company may obtain FDA approval before patent expiry if it certifies its product does not infringe the listed patents or the patents are invalid (paragraph IV certification). In addition, the first company to file an ANDA with paragraph IV certification is awarded a 180-day period of exclusivity for the ensuing generic product, giving the filer an important competitive advantage. Bioequivalent generic versions of drugs that are not protected by patents can be produced and marketed in the U.S. by any company, subject to FDA approval.

Who Are the Movers and Shakers This Quarter?

Molecules recently exposed to paragraph IV challenges: Big Pharma companies such as sanofi-aventis, Eli Lilly, Hoffmann-La Roche and AstraZeneca all saw challenges in the period from July to September on molecules they have patented.

Companies taking their first steps into the US generics industry: The report highlights companies that were felt to be of significant interest. This quarter, the report focuses on Dabur India Ltd, who launched a Paragraph IV challenge on the drug oxaliplatin, Zhejiang Huahai Pharmaceutical Group Co Ltd, a Chinese company that has received tentative approval for nevirapine 200mg tablets under the President's Emergency Plan for Aids Relief (PEPAR) program, and GeneraMedix Pharmaceuticals Inc., an American company based in New Jersey that has received FDA approval for a selection of new products.

"The global stakes involved in the US generics market become evident when you see that the top country filing ANDAs in the US is India, and the company recorded as having the most Paragraph IV patent challenges is Teva, an Israeli Pharma company," added Kuhrt. "Clearly, the message is that American companies cannot presume that they will have a home advantage in this market."

About This Quarterly Report:

Data for this report was compiled and analyzed using Newport Horizon Global(R) a critical product targeting and global business development system from Thomson Scientific. Created specifically for generic pharmaceutical companies and strategic API manufacturers, it allows them to identify and evaluate product opportunities worldwide, ensuring they will be the first to find the generic product and niche opportunity, first to make the deal, and first to get to market.

For a copy of the full report with analysis, visit:

(To view the following url, please copy and paste it into a new browser.) http://scientific.thomson.com/thomsonpharma/media/pdfs/tpqr/m-a-s-jul- sep07.pdf

About The Thomson Corporation

The Thomson Corporation (http://www.thomson.com) is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development-from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at scientific.thomson.com.


'/>"/>
SOURCE The Thomson Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Jobson Medical Information LLC Acquires CenterWatch and New England IRB From Thomson Healthcare
2. Saint Barnabas Health Care System Expands Business Relationship with Thomson Healthcare
3. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
4. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
5. Thomson Scientific Takes a Fresh Look at Multiauthor Papers
6. Thomson Healthcare Study Finds That Hospitals Delivering High-Quality Heart Care Are Efficient and Cost Effective, Too
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - a Quarterly Review of Scientific Literature on Drugs and Therapies From July - September 2007
8. Thomson Healthcare Launches Application That Assesses Physician Performance
9. Contract Renewal Extends Thomson Healthcares Long-Standing Relationship with University Hospitals
10. Thomson Scientific Launches Confessions ... of a User Campaign Asking Are You the New Face of Research?
11. Thomson Scientific Ranks Australian Universities and Research Institutes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... TherapySites, the leading website ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to ... adding exclusive benefits and promotional offers. , "TCA is extremely excited about this ...
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 26, 2016 One of Australia,s ... formation of a new biotechnology company, Noxopharm Limited [ABN 50 608 ... IPO and to list on the ASX. Noxopharm is ... to enter a Phase 1 clinical study later this year. ... one of the biggest problems facing cancer patients - the ability ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology: